Shares of pharmaceutical company Rubicon Research Ltd on Thursday listed with a premium of nearly 28 per cent against the issue price of ₹485.
The stock started trading at ₹620.10, up 27.85 per cent, from the issue price on the BSE.
At the NSE, the stock made its debut at ₹620, registering a jump of 27.83 per cent.
The company’s market valuation stood at ₹9,917.97 crore.
The initial public offer of Rubicon Research garnered 103.90-times subscription on the closing day of bidding on Monday.
The ₹ 1,377.5-crore IPO had a price band of ₹461-485 per share.
The company’s initial public offering (IPO) had a fresh issue of equity shares worth ₹500 crore and an Offer-For-Sale (OFS) of ₹877.5 crore by the promoter, General Atlantic Singapore RR Pte Ltd.
Proceeds from the fresh issue to the tune of ₹310 crore would be used for debt repayment, and a portion would be allocated for inorganic growth through acquisitions, strategic initiatives, and general corporate purposes.
Rubicon Research is a pharmaceutical formulation company with a strong focus on R&D and innovation. Its portfolio includes an increasing number of speciality products and drug-device combination products targeting regulated markets, particularly the United States.
The company has also been expanding its manufacturing footprint. In June, it acquired Alkem Laboratories’ formulations facility in Pithampur, Madhya Pradesh, in an all-cash deal worth ₹149 crore.
It currently operates two US FDA-inspected R&D facilities — one in India and another in Canada — along with two manufacturing plants in India accredited by multiple regulatory authorities, including USFDA, Maharashtra FDA (WHO-GMP), and Health Canada.
Published on October 16, 2025
